journal article·2014-11-12

Core–Shell Nanoparticles Based on Pullulan and Poly(β-amino) Ester for Hepatoma-Targeted Codelivery of Gene and Chemotherapy Agent

Yuanyuan Liu, Yan Wang, Cong Zhang, Ping Zhou, Yang Liu, Tong An, Duxin Sun, Ning Zhang, Yinsong Wang

Publisher page

Abstract

This study designs a novel nanoparticle system with core-shell structure based on pullulan and poly(β-amino) ester (PBAE) for the hepatoma-targeted codelivery of gene and chemotherapy agent. Plasmid DNA expressing green fluorescent protein (pEGFP), as a model gene, was fully condensed with cationic PBAE to form the inner core of PBAE/pEGFP polycomplex. Methotrexate (MTX), as a model chemotherapy agent, was conjugated to pullulan by ester bond to synthesize polymeric prodrug of MTX-PL. MTX-PL was then adsorbed on the surface of PBAE/pEGFP polycomplex to form MTX-PL/PBAE/pEGFP nanoparticles with a classic core-shell structure. MTX-PL was also used as a hepatoma targeting moiety, because of its specific binding affinity for asialoglycoprotein receptor (ASGPR) overexpressed by human hepatoma HepG2 cells. MTX-PL/PBAE/pEGFP nanoparticles realized the efficient transfection of pEGFP in HepG2 cells and exhibited significant inhibitory effect on the cell proliferation. In HepG2 tumor-bearing nude mice, MTX-PL/PBAE/pEGFP nanoparticles were mainly distributed in the tumor after 24 h postintravenous injection. Altogether, this novel codelivery system with a strong hepatoma-targeting property achieved simultaneous delivery of gene and chemotherapy agent into tumor at both cellular and animal levels.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Immunotherapy and Immune Responses · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Tianjin Cancer Institute and Hospital, Laboratory of Breast Cancer Prevention and Therapy, Ministry of Education, Research Center of Basic Medical Science & School of Pharmacy, Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), Tianjin Medical University, No. 22 Qixiangtai Road, Heping District, Tianjin 300070, People’s Republic of China

Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, United States

Funding

Ministry of Science and Technology of the People's Republic of China · National Natural Science Foundation of China

References (38)

Show source-provided references
1. Parkin D. M. · Int. J. Cancer · 2001 · 94 · 15310.1002/ijc.1440 ↗
2. Altekruse S. F. · J. Clin. Oncol. · 2009 · 27 · 148510.1200/JCO.2008.20.7753 ↗
3. Lau W.-Y · Hepatobiliary Pancreatic Dis. Int. · 2008 · 7 · 237
4. Blum H. E. · World J. Gastroenterol. · 2005 · 11 · 7391
5. Cahill B. A. · Clin. J. Oncol. Nurs. · 2004 · 8 · 39310.1188/04.CJON.393-399 ↗
6. Decadt B. · Lancet Oncol. · 2004 · 5 · 55010.1016/S1470-2045(04)01567-0 ↗
7. Ishikawa H. · Hepatology · 2003 · 37 · 69610.1053/jhep.2003.50077 ↗
8. Hwang L.-H. · J. Biomed. Sci. · 2006 · 13 · 45310.1007/s11373-006-9085-7 ↗
9. Hernández-Alcoceba R. · Ann. Hepatol. · 2007 · 6 · 510.1016/S1665-2681(19)31948-9 ↗
10. McMenamin M. M. · Clin. Oncol. Cancer Res. · 2011 · 8 · 1010.1007/s11805-011-0551-2 ↗
11. Xu Q. · Biomaterials · 2013 · 34 · 514910.1016/j.biomaterials.2013.03.044 ↗
12. Jacobs F. · Pharmaceuticals · 2012 · 5 · 137210.3390/ph5121372 ↗
13. Thomas C. E. · Nat. Rev. Genet. · 2003 · 4 · 34610.1038/nrg1066 ↗
14. Kaufmann K. B. · EMBO Mol. Med. · 2013 · 5 · 164210.1002/emmm.201202287 ↗
15. Niidome T. · Gene Ther. · 2002 · 9 · 164710.1038/sj.gt.3301923 ↗
16. Zhang Y. · Mol. Ther. · 2012 · 20 · 129810.1038/mt.2012.79 ↗
17. Ding B. · Curr. Gene Ther. · 2012 · 12 · 9210.2174/156652312800099625 ↗
18. Morille M. · Biomaterials · 2008 · 29 · 347710.1016/j.biomaterials.2008.04.036 ↗
19. Canine B. F. · Adv. Drug Delivery Rev. · 2010 · 62 · 152410.1016/j.addr.2010.04.001 ↗
20. Ibraheem D. · Int. J. Pharm. · 2014 · 459 · 7010.1016/j.ijpharm.2013.11.041 ↗
21. Anderson D. G. · Proc. Natl. Acad. Sci. U.S.A. · 2004 · 101 · 1602810.1073/pnas.0407218101 ↗
22. Green J. J. · Nano Lett. · 2007 · 7 · 87410.1021/nl062395b ↗
23. Lee J.-S. · Nano Lett. · 2009 · 9 · 240210.1021/nl9009793 ↗
24. Fields R. J. · J. Controlled Release · 2012 · 164 · 4110.1016/j.jconrel.2012.09.020 ↗
25. Gu J. · Biomaterials · 2012 · 33 · 64410.1016/j.biomaterials.2011.09.076 ↗
26. Leathers T. D. · Appl. Microbial. Biotechnol. · 2003 · 62 · 46810.1007/s00253-003-1386-4 ↗
27. Singha R. S. · Carbohydr. Polym. · 2008 · 73 · 51510.1016/j.carbpol.2008.01.003 ↗
28. Moghimi S. M. · Pharmacol. Rev. · 2001 · 53 · 28310.1016/S0031-6997(24)01494-7 ↗
29. Kaneo Y. · J. Controlled Release · 2001 · 70 · 36510.1016/S0168-3659(00)00368-0 ↗
30. Tang H.-B. · Drug Delivery · 2010 · 17 · 55210.3109/10717544.2010.490250 ↗
31. Wang Y. · Biomaterials · 2013 · 34 · 718110.1016/j.biomaterials.2013.05.081 ↗
32. Hossain M. A. · Int. J. Oncol. · 2012 · 40 · 129810.3892/ijo.2011.1304 ↗
33. Davis B. G. · Curr. Opin. Drug Discovery Dev. · 2002 · 5 · 279
34. Medina S. H. · Biomaterials · 2011 · 32 · 411810.1016/j.biomaterials.2010.11.068 ↗
35. Guo R. · RSC Adv. · 2012 · 2 · 9910.1039/C1RA00320H ↗
36. Nishida K. · Pharm. Res. · 1991 · 8 · 125310.1023/A:1015895511208 ↗
37. Grandinetti G. · Mol. Pharmaceutics · 2012 · 9 · 52310.1021/mp200368p ↗
38. Fischer D. · Biomaterials · 2003 · 24 · 112110.1016/S0142-9612(02)00445-3 ↗